Capsule Summary Slidesets

Share

Program Content

Activities

  • TRANSCEND CLL 004
    Phase I/II TRANSCEND CLL 004: Lisocabtagene Maraleucel (JCAR017) in R/R CLL/SLL After BTK Inhibition Failure
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 07, 2019

    Expires: June 05, 2020

  • CLL14: Venetoclax/Obinutuzumab
    Phase III CLL14: Venetoclax + Obinutuzumab vs Chlorambucil + Obinutuzumab in Patients With Previously Untreated CLL and Comorbidities
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 10, 2019

    Expires: June 08, 2020

  • Umbralisib in MZL
    UNITY-NHL Phase IIb Trial: Efficacy and Safety of Umbralisib Monotherapy in Patients With R/R Marginal Zone Lymphoma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 07, 2019

    Expires: June 05, 2020

  • Smart Start: RLI in DLBCL
    Phase II Smart Start: Ibrutinib, Lenalidomide, and Rituximab + Chemotherapy in Newly Diagnosed Non-GCB DLBCL
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 11, 2019

    Expires: June 09, 2020

  • E3A06: Len in SMM
    E3A06: Phase II/III Study of Lenalidomide vs Observation in Asymptomatic, High-Risk Smoldering Multiple Myeloma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 05, 2019

    Expires: June 03, 2020

  • Updated FORTE Results
    Phase II FORTE: Efficacy of KRd With or Without ASCT in Newly Diagnosed Multiple Myeloma According to Risk Status
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 03, 2019

    Expires: June 01, 2020

  • Iberdomide in R/R MM
    Iberdomide Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase Ib/IIa Dose Escalation Study
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 07, 2019

    Expires: June 05, 2020

  • AMG 420 Data in R/R MM
    Updated Results From Phase I Trial of AMG 420, an Anti-BCMA Bispecific T-Cell Engager, in Patients With Relapsed/Refractory Multiple Myeloma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 04, 2019

    Expires: June 02, 2020

Provided by

ProCE Banner

Supporters

Amgen, Inc.

Astellas Seattle Genetics

Bayer Healthcare Pharma

Blueprint Medicines

Celgene

Novartis Pharmaceuticals Corporation

Puma Biotechnology, Inc.

Taiho Oncology Inc

Tesaro